Equities research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research note issued on Saturday. The firm set a “sell” rating on the stock.
Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price target on shares of VolitionRx in a research note on Wednesday, March 27th.
View Our Latest Report on VNRX
VolitionRx Stock Up 1.4 %
VolitionRx (NYSE:VNRX – Get Free Report) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, equities analysts expect that VolitionRx will post -0.4 earnings per share for the current fiscal year.
Hedge Funds Weigh In On VolitionRx
An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in VolitionRx Limited (NYSE:VNRX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors and hedge funds.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Read More
- Five stocks we like better than VolitionRx
- Using the MarketBeat Dividend Tax Calculator
- MarketBeat Week in Review – 4/29 – 5/3
- What is Put Option Volume?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.